California is currently home to 5608 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Long-Term Follow-up Protocol
Recruiting
The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).
Gender:
ALL
Ages:
6 months and above
Trial Updated:
06/07/2021
Locations: Mission Dermatology Center, Rancho Santa Margarita, California
Conditions: Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
Recruiting
feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2021
Locations: University of California Los Angeles (UCLA), Los Angeles, California
Conditions: Rectal Adenocarcinoma
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies, the PROCEED Study
Recruiting
This study gathers information on patients at different stages of chronic pancreatitis to better understand the natural course and risk factors associated with pancreatitis. Chronic pancreatitis is a disease that occurs when the pancreas is inflamed (swollen and irritated) all of the time. It is important for doctors to diagnose chronic pancreatitis in the beginning stages of the disease. Over time, as chronic pancreatitis gets worse, the pancreas may stop working correctly. Since treatment opti... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/22/2021
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Acute Pancreatitis, Chronic Pancreatitis
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
Recruiting
The investigators are researching families with inherited inclusion body myopathy (IBM) and/or Paget disease of bone (PDB) and/or dementia (FTD) which is also called IBMPFD. IBMPFD is caused by mutations in the VCP gene. Our main goal is to understand how changes in the VCP gene cause the muscle, bone and cognitive problems associated with the disease. The investigators are collecting biological specimen such as blood and urine samples, family and medical histories, questionnaire data of patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/07/2021
Locations: University of California, Irvine, Irvine, California
Conditions: Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia, Paget Disease of Bone, Frontotemporal Dementia, Myopathy
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Recruiting
Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2021
Locations: Scripps Clinic Torrey Pines, La Jolla, California
Conditions: Carcinoma, Hepatocellular
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Recruiting
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2021
Locations: CCARE, Fresno, California
Conditions: Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Chula Vista, California
Conditions: Ulcerative Colitis
Open-Label Extension Study of BION-1301 in IgA Nephropathy
Recruiting
This is an open-label extension (OLE) study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of BION-1301 in adults with IgA nephropathy
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2020
Locations: Amicis Research Center, Northridge, California
Conditions: IgA Nephropathy
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: California Pharmaceutical Research Institute, Inc., Anaheim, California
Conditions: Schizophrenia
Filter Initial & Long Term Evaluation After Placement and Retrieval Registry
Recruiting
A prospective data registry for all patients who undergo IVC (Inferior Vena Cava) filter placement or retrieval at Stanford. Potential enrollees will already be undergoing the procedure. If patients are willing, they will be prospectively enrolled prior to the procedure. As part of the study, chart and clinical data reviews will be used to track patient progress and response to the treatment.
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2020
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Venous Thromboembolism
Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis
Recruiting
Sarcoidosis is a multi-system granulomatous disorder that is triggered and influenced by gene-environment interactions. Although sarcoidosis predominantly affects the lungs in most cases, the clinical disease course is highly variable and any organ can be affected leading to end organ damage despite currently available therapeutics that unfortunately also have numerous and potentially devastating side effects. The environmental triggers of sarcoidosis are unknown but several occupational, enviro... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/04/2020
Locations: University of California, San Francisco (Parnassus), San Francisco, California
Conditions: Sarcoidosis, Sarcoidosis, Pulmonary
Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata
Recruiting
The primary objective of this study is to evaluate the safety and efficacy of the use of a biocellular mixture of emulsified adipose-derived tissue stromal vascular fraction (AD-tSVF) and high density platelet-rich plasma concentrate (HD- PRP). Additionally, comparison with clinical outcomes of adipose-derived cellular Stromal Vascular Fraction (AD-cSVF) + AD-tSVF + HD PRP; AD-cSVF + emulsified AD-tSVF + HD- PRP; emulsified AD-tSVF + HD PRP + AD-cSVF; AD-cSVF via intravenous infusion in treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2020
Locations: Kenneth Williams, DO, Irvine, California
Conditions: Alopecia Areata, Scarring Alopecia